切换至 "中华医学电子期刊资源库"

中华脑血管病杂志(电子版) ›› 2023, Vol. 17 ›› Issue (03) : 227 -231. doi: 10.11817/j.issn.1673-9248.2023.03.006

临床研究

血小板抑制不足与颈动脉支架植入术后不良事件的相关性研究
黎力梦, 陶悦, 刘坚军, 李旭, 王晓俊, 汪涛, 陈斌, 范隆华()   
  1. 201700 上海,复旦大学附属中山医院青浦分院血管外科
    201700 上海,复旦大学附属中山医院青浦分院血管外科;200032 上海,复旦大学附属中山医院血管外科
  • 收稿日期:2023-01-23 出版日期:2023-06-01
  • 通信作者: 范隆华
  • 基金资助:
    上海市自然基金(22ZR1412100)

Association between inadequate platelet inhibition and adverse events after carotid artery stenting

Limeng Li, Yue Tao, Jianjun Liu, Xu Li, Xiaojun Wang, Tao Wang, Bin Chen, Longhua Fan()   

  1. Department of Vascular Surgery, QingPu Branch of Zhongshan Hospital, Fudan University, Shanghai 201700, China
    Department of Vascular Surgery, QingPu Branch of Zhongshan Hospital, Fudan University, Shanghai 201700, China; Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai 2000032, China
  • Received:2023-01-23 Published:2023-06-01
  • Corresponding author: Longhua Fan
引用本文:

黎力梦, 陶悦, 刘坚军, 李旭, 王晓俊, 汪涛, 陈斌, 范隆华. 血小板抑制不足与颈动脉支架植入术后不良事件的相关性研究[J/OL]. 中华脑血管病杂志(电子版), 2023, 17(03): 227-231.

Limeng Li, Yue Tao, Jianjun Liu, Xu Li, Xiaojun Wang, Tao Wang, Bin Chen, Longhua Fan. Association between inadequate platelet inhibition and adverse events after carotid artery stenting[J/OL]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(03): 227-231.

目的

分析血小板抑制率与颈动脉支架植入术(CAS)后不良事件的相关性。

方法

回顾性分析2016年1月至2022年6月复旦大学附属中山医院青浦分院149例CAS患者的临床资料,所有患者均通过血栓弹力图(TEG)评估术前血小板功能,根据有无术后不良事件分为结局不良组与结局良好组。采用t检验比较结局良好组与结局不良组组间血小板抑制率的差异,通过单因素、多因素Logistic回归分析及受试者操作特征(ROC)曲线分析血小板抑制率与不良事件的相关性。

结果

不良事件发生率为10.7%(16/149),结局良好组患者二磷酸腺苷(ADP)抑制率大于结局不良组(44.4%±23.5% vs 30.3%±17.8%),差异具有统计学意义(t=2.310,P=0.022)。单因素、多因素Logistic回归分析显示,较低的ADP抑制率(OR=0.45,95%CI:0.003~0.64,P=0.022)是术后不良事件的独立危险因素。ROC曲线分析显示,ADP抑制率预测CAS术后不良事件的曲线下面积为0.679(95%CI:0.557~0.802,P=0.019)。

结论

CAS术后不良事件与ADP抑制率不足有关,根据血小板功能检测结果调整抗血小板方案或可降低CAS术后并发症的发生率。

Objective

To analyze the correlation of the platelet inhibition rate with adverse events after carotid artery stenting (CAS).

Methods

A total of 149 CAS patients from QingPu Branch of Zhongshan Hospital Affiliated to Fudan University between January 2016 and June 2022 were retrospectively analyzed. All patients had preoperative platelet function assessed by thromboelastography (TEG) and were divided into two groups with poor outcomes versus good outcomes according to the presence or absence of postoperative adverse events. The t-test was used to compare the differences in platelet inhibition rate between the groups with good and poor outcomes, Univariate and multivariate logistic regression analysis, receiver operating characteristic (ROC) curve were used to analyze the association between platelet inhibition rate and adverse events.

Results

The incidence of adverse events was 10.7% (16/149), with a statistically significant difference in adenosine diphosphate (ADP) inhibition between patients with good and adverse outcomes (44.4%±23.5% vs 30.3%±17.8%, t=2.310, P=0.022). Inadequate ADP inhibition (OR=0.45, 95%CI: 0.003-0.64, P=0.022) was risk factor for postoperative adverse events. ROC curve analysis showed that the area under the curve for predicting ADP inhibition after CAS adverse events was 0.679 (95%CI: 0.557-0.802, P=0.019).

Conclusion

Adverse events post-CAS are associated with ADP inhibition, and a personalized antiplatelet treatment plan based on plalet assessmentmay reduce the incidence of CAS complications.

表1 颈内动脉狭窄患者不同结局组临床基本资料及TEG参数比较
图1 二磷酸腺苷(ADP)抑制率预测颈动脉内膜狭窄患者颈动脉支架置入术后不良事件的受试者操作特征曲线
1
Collaborators GBDS. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019 [J]. Lancet Neurol, 2021, 20(10): 795-820.
2
中华医学会外科学分会血管外科学组. 颈动脉狭窄诊治指南 [J]. 中国血管外科杂志(电子版), 2017, 9(3): 169-175.
3
Naylor AR, Rantner B, Ancetti S, et al. European society for vascular surgery (ESVS) 2023 Clinical practice guidelines on the management of atherosclerotic carotid and vertebral artery disease [J]. Eur J Vasc Endovasc Surg, 2022, 20: S1078-5884(22)00237-4.
4
王涛. 颈动脉疾病及其相关缺血性脑卒中的治疗现状与展望 [J/OL]. 中华脑血管病杂志(电子版), 2022, 16(6): 373-378.
5
Muller MD, Lyrer P, Brown MM, et al. Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis [J]. Cochrane Database Syst Rev, 2020, 2(2): CD000515.
6
Kim Y, Patel SS, McElroy IE, et al. A systematic review of thromboelastography utilization in vascular and endovascular surgery [J]. J Vasc Surg, 2022, 75(3): 1107-1115.
7
Stuckey TD, Kirtane AJ, Brodie BR, et al. Impact of aspirin and clopidogrel hyporesponsiveness in patients treated with drug-eluting stents: 2-year results of a prospective, multicenter registry study [J]. JACC Cardiovasc Interv, 2017, 10(16): 1607-1617.
8
刘玲, 侯华娟, 刘亚红, 等. 用血栓弹力图评价阿司匹林及氯吡格雷在缺血性卒中患者中血小板抑制效应的研究 [J]. 中风与神经疾病杂志, 2012, 29(5): 446-449.
9
Sakai T. Comparison between thromboelastography and thromboelastometry [J]. Minerva Anestesiol, 2019, 85(12): 1346-1356.
10
季汉华, 陈娜. 血栓弹力图监测糖尿病患者经皮冠状动脉介入术后抗血小板药物抵抗的发生率 [J/CD]. 中华临床医师杂志(电子版), 2012, 6(16): 4848-4850.
11
Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? [J]. J Am Coll Cardiol, 2007, 49(6): 657-666.
12
Hill MD, Brooks W, Mackey A, et al. Stroke after carotid stenting and endarterectomy in the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) [J]. Circulation, 2012, 126(25): 3054-3061.
13
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the global burden of disease study 2017 [J]. Lancet (London, England), 2019, 394(10204): 1145-1158.
14
Bonati LH, Jansen O, de Borst GJ, et al. Management of atherosclerotic extracranial carotid artery stenosis [J]. Lancet Neurol, 2022, 21(3): 273-283.
15
Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study[published correction appears in Lancet. 2014 Mar 29;383(9923):1128] [J]. Lancet, 2013, 382(9892): 614-623.
16
Wang B, Li XQ, Ma N, et al. Association of thrombelastographic parameters with post-stenting ischemic events [J]. J Neurointerv Surg, 2017, 9(2): 192-195.
17
Hawkins BM, Kennedy KF, Giri J, et al. Pre-procedural risk quantification for carotid stenting using the CAS score: a report from the NCDR CARE registry [J]. J Am Coll Cardiol, 2012, 60(17): 1617-1622.
18
White CJ, Ramee SR, Collins TJ, et al. Carotid artery stenting: patient, lesion, and procedural characteristics that increase procedural complications [J]. Catheter Cardiovasc Interv, 2013, 82(5): 715-726.
19
Setacci C, Chisci E, Setacci F, et al. Siena carotid artery stenting score: a risk modelling study for individual patients [J]. Stroke, 2010, 41(6): 1259-1265.
20
王翩, 王琰, 李虹庆. 颈动脉支架置入术后支架内血栓形成研究进展 [J]. 中国卒中杂志, 2019, 14(6): 625-629.
21
Yang H, Li Y, Jiang Y. Insufficient platelet inhibition and thromboembolic complications in patients with intracranial aneurysms after stent placement [J]. J Neurosurg, 2016, 125(2): 247-253.
[1] 王振宇, 张洪美, 荆琳, 何名江, 闫奇. 膝骨关节炎相关炎症因子与血浆代谢物间的因果关系及中介效应[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 467-473.
[2] 李亚龙, 王星童, 申传安. 异体富血小板血浆在创面修复中的临床应用进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 541-545.
[3] 黄鸿初, 黄美容, 温丽红. 血液系统恶性肿瘤患者化疗后粒细胞缺乏感染的危险因素和风险预测模型[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 285-292.
[4] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[5] 康婵娟, 张海涛, 翟静洁. 胰管支架置入术治疗急性胆源性胰腺炎的效果及对患者肝功能、炎症因子水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 667-670.
[6] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[7] 林凯, 潘勇, 赵高平, 杨春. 造口还纳术后切口疝的危险因素分析与预防策略[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 634-638.
[8] 杨闯, 马雪. 腹壁疝术后感染的危险因素分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 693-696.
[9] 马振威, 宋润夫, 王兵. ERCP胆道内支架与骑跨十二指肠乳头支架置入治疗不可切除肝门部胆管癌疗效的Meta分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 807-812.
[10] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[11] 张龙, 孙善柯, 徐伟, 李文柱, 李俊达, 池涌泉, 何广胜, 成峰, 王学浩, 饶建华. 腹腔镜脾切除治疗血液系统疾病的临床疗效分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 870-875.
[12] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[13] 石阳, 于剑锋, 曹可, 翟志伟, 叶春祥, 王振军, 韩加刚. 可扩张金属支架置入联合新辅助化疗治疗完全梗阻性左半结肠癌围手术期并发症分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 464-471.
[14] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[15] 颜世锐, 熊辉. 感染性心内膜炎合并急性肾损伤患者的危险因素探索及死亡风险预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 618-624.
阅读次数
全文


摘要